Cholesterol Drug May Weaken Ovarian Cancer’s Metastatic Defense
Preclinical research suggests that peritoneal ascites may protect metastatic ovarian cancer cells from ferroptosis, helping the cancer cells survive and spread, and that this protection may be disrupted using a decades-old cholesterol-lowering drug, bezafibrate. The post Cholesterol Drug May Weaken Ovarian Cancer’s Metastatic Defense appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Source
Read the full article at Genengnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.